This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biroscak, B. J.
Right arrow Articles by Stoltman, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biroscak, B. J.
Right arrow Articles by Stoltman, G.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Hepatitis B
PEDIATRICS Vol. 111 No. 6 June 2003, pp. e645-e649

ELECTRONIC ARTICLE

Impact of the Thimerosal Controversy on Hepatitis B Vaccine Coverage of Infants Born to Women of Unknown Hepatitis B Surface Antigen Status in Michigan

Brian J. Biroscak, MS*, Anthony E. Fiore, MD, MPH{ddagger}, Nancy Fasano, MA*, Patrick Fineis, BA*, Michael P. Collins, MD§ and Gillian Stoltman, PhD, MPH*

* Communicable Disease and Immunization Division, Michigan Department of Community Health, Lansing, Michigan
{ddagger} Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia
§ Michigan State University and Health Departments of Grand Traverse, Benzie, and Leelanau Counties, Lansing, Michigan

Objective. Hepatitis B vaccine is recommended for all infants, and the series may be started during the delivery admission. For infants who are born either to women who are positive for hepatitis B surface antigen (HBsAg) or to women whose HBsAg status is unknown, vaccination should be started within 12 hours of birth to prevent perinatal and early childhood hepatitis B virus infection. Because of concerns about mercury exposures from vaccines that contain thimerosal, the United States Public Health Service (USPHS) and the American Academy of Pediatrics (AAP) recommended in July 1999 that the first dose of hepatitis B vaccine be deferred until 2–6 months of age but only for infants who are born to HBsAg-negative women. To assess the impact on birth-dose vaccine coverage for infants who are born to women with unknown HBsAg status, we measured coverage before and after July 1999.

Methods. A sample of Michigan infants who were born to women whose HBsAg status was either unknown or missing were identified by reviewing newborn screening cards for infants who were born during 1) March–April 1999 (before recommendation changes [T1]); 2) July 15–September 15, 1999 (immediately after recommendation changes [T2]); and 3) March–April 2000 (6 months after resumption of pre-1999 practices were recommended [T3]). We verified maternal HBsAg screening and newborn hepatitis B vaccination by reviewing infant and maternal hospital records.

Results. Of 1201 infants who were born to women whose HBsAg status was indicated as unknown or missing on the newborn screening card during the 3 time periods, 216 (18%) were born to women whose status was truly unknown at the time of delivery, as determined by medical record review. During T1, 53% of these 216 infants received hepatitis B vaccine before hospital discharge, compared with 7% of infants who were born during T2 and 57% of infants who were born during T3. During T1, 19% of these infants received hepatitis B vaccine within 12 hours of birth compared with 1% of infants who were born during T2 and 14% of infants who were born during T3.

Conclusions. Hepatitis B vaccine birth-dose coverage for infants who were born to women whose HBsAg status was unknown at the time of delivery was already low in Michigan before the July 1999 USPHS/AAP Joint Statement but decreased significantly during the 2 months after the USPHS/AAP Joint Statement. Abrupt changes in established vaccination recommendations for lower risk children may lead to decreased coverage among higher risk children. Increases in hepatitis B vaccine coverage at birth are necessary to reduce the risk of perinatal infection for infants who are born to women with unknown HBsAg status.

Key Words: infant vaccination • hepatitis B vaccine, thimerosal • vaccine coverage • birth dose • vaccine coverage • vaccine safety

Abbreviations: HBsAg, hepatitis B surface antigen • HBV, hepatitis B virus • AAP, American Academy of Pediatrics • USPHS, United States Public Health Service • CDC, Centers for Disease Control and Prevention • MDCH, Michigan Department of Community Health • OR, odds ratio • CI, confidence interval

Received for publication Oct 2, 2002; Accepted Dec 30, 2002.




This article has been cited by other articles:


Home page
 JAMAHome page
E. T. Luman, A. E. Fiore, T. W. Strine, and L. E. Barker
Impact of Thimerosal-Related Changes in Hepatitis B Vaccine Birth-Dose Recommendations on Childhood Vaccination Coverage
JAMA, May 19, 2004; 291(19): 2351 - 2358.
[Abstract] [Full Text] [PDF]